- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Protein Structure Prediction Market Size, Share | CAGR 28.6%
Global Protein Structure Prediction Market Size, Share & Industry Analysis By Offering (Software and Platforms, Databases and Knowledge Repositories, Cloud-Based Prediction, Computational Biology and Bioinformatics Solutions), By Technology (Artificial Intelligence-Based, Machine Learning Algorithms, Homology Modeling, Ab Initio Modeling, Molecular Dynamics Simulation and Deep Learning-Based), By Application (Drug Discovery, Protein Engineering, Precision Medicine, Antibody Design, Vaccine Development and Biomarker Discovery), By End-User, Industry Region & Key Players – Market Dynamics, Competitive Strategies, Trends & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026-2034) | Largest Region (2025) |
|---|---|---|---|
| USD 0.42 Billion | USD 4.05 Billion | 28.6% | North America, 41.0% |
The Protein Structure Prediction Market was valued at USD 0.33 Billion in 2024 and USD 0.42 Billion in 2025. The market is projected to reach USD 4.05 Billion by 2034, expanding at a CAGR of 28.6% during the forecast period from 2026 to 2034. The increasing adoption of artificial intelligence in computational biology, rising demand for accelerated drug discovery, and growing applications in biologics development and precision medicine are expected to drive remarkable market growth throughout the forecast period. This represents an absolute dollar opportunity of USD 3.63 Billion over the analysis period.
Protein Structure Prediction Market Global Forecast to 2034 (USD)
CAGR OF
28.6%
Protein Structure Prediction Market
Get more details on this report -
Demand is anchored by the AlphaFold ecosystem, which now serves over 3 million researchers across more than 190 countries according to Google DeepMind November 2025 disclosure. The AlphaFold Protein Structure Database hosts over 200 million predicted structures in collaboration with the European Bioinformatics Institute at EMBL-EBI. AlphaFold 3, released in May 2024, extended structural prediction to proteins, DNA, RNA, ligands, ions, and post-translational modifications, and surpassed traditional methods on the PoseBusters benchmark by 50% according to the May 2024 Nature publication.
Regulatory and scientific recognition accelerated commercial momentum. The 2024 Nobel Prize in Chemistry, awarded on 9 October 2024 to Demis Hassabis, John Jumper, and David Baker, validated computational protein structure prediction as a foundational scientific discipline. The U.S. Food and Drug Administration accepted more than 500 submissions referencing AI-derived molecules between 2016 and 2023, and the FDA issued the first-ever Orphan Drug Designation for an AI-discovered molecule (Insilico Medicine's INS018_055) in February 2023, creating regulatory precedent for downstream therapies that depend on protein structure prediction.
Pharmaceutical R&D budgets remain the principal demand driver, supported by over USD 1.7 billion in disclosed AI-protein-design partnership upfronts during the trailing 18 months. Schrödinger, Inc. (Nasdaq: SDGR) reported USD 180.4 million in 2024 software revenue and entered a USD 150 million upfront collaboration with Novartis in January 2025 carrying potential milestones up to USD 2.3 billion. Isomorphic Labs raised USD 600 million from Thrive Capital and Alphabet in April 2025, while Generate Biomedicines filed for a Nasdaq IPO under the ticker GENB on 4 February 2026 after attracting over USD 700 million in cumulative private funding.
North America held 41.0% of the protein structure prediction market in 2025, supported by deep biotech infrastructure, NIH funding pipelines, and concentration of pharma R&D spending. Asia Pacific is positioned as the fastest-growing region through 2034, with China, Japan, South Korea, and Singapore investing in domestic AI-biology platforms. The protein structure prediction market outlook through 2034 reflects three convergent drivers: continued accuracy gains from diffusion-based architectures and protein language models, expansion into protein-ligand and antibody-antigen prediction relevant to drug discovery, and structural integration with cryo-electron microscopy and high-throughput experimental platforms across pharmaceutical R&D pipelines.
Market Definition & Scope
The protein structure prediction market is defined as the global commercial activity surrounding software, cloud platforms, and integrated services that computationally predict three-dimensional protein conformations and biomolecular complexes from amino acid sequence data. The market encompasses deep learning models such as AlphaFold 3, RoseTTAFold, ESMFold, OmegaFold, and I-TASSER, physics-based suites including Schrödinger Maestro and BIOVIA Discovery Studio, and integrated AI drug design engines such as Isomorphic Labs IsoDDE and the Generate Platform.
This analysis covers software licensing, cloud-based subscription access, on-premises GPU deployments, integrated drug discovery collaborations tied to structure prediction, and academic open-access platforms with commercial monetization tiers, serving pharmaceutical, biotechnology, academic research, and contract research organization end-users across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The analysis explicitly excludes experimental structural biology instrumentation (X-ray crystallography, cryo-EM hardware, NMR spectrometers), wet-lab antibody discovery services without computational structure prediction components, and broad protein engineering platforms that do not depend on structure prediction. The protein structure prediction market sits within the parent structural biology and molecular modeling category, which industry tracking estimates at USD 9.55 Billion in 2025.
Key Takeaways
- Market Growth: The protein structure prediction market expanded from USD 0.42 Billion in 2025 toward a projected USD 4.05 Billion by 2034 at a 28.6% CAGR, creating a USD 3.63 Billion absolute dollar opportunity.
- Segment Dominance (Offering): Software and platform licensing held approximately 68.5% of the protein structure prediction market in 2025, with services (collaborations, custom modeling) representing the balance.
- Segment Dominance (Application): Drug discovery and lead optimization led with 33.7% revenue share in 2025, supported by structure-based design programs at all top 20 pharmaceutical companies.
- Driver: Pharmaceutical R&D adoption is intense, with more than 500 FDA submissions referencing AI components between 2016 and 2023 and over USD 1.7 billion in disclosed AI-protein-design partnership upfronts in the trailing 18 months.
- Restraint: Reliability gaps remain, including AlphaFold 3 generalization weaknesses on protein-ligand structures dissimilar to training data documented by the Runs N' Poses benchmark in 2025.
- Opportunity: De novo protein design represents the highest-growth subdomain, with Generate Biomedicines, EvolutionaryScale, and the Baker Lab demonstrating wet-lab-validated functional proteins designed entirely in silico.
- Trend: Diffusion-based generative architectures (AlphaFold 3, RFdiffusion, ESM3) are replacing earlier evoformer and template-based approaches, enabling joint sequence-structure-function modeling.
- Regional: North America led with 41.0% market share in 2025 (approximately USD 0.17 Billion), supported by NIH research funding and concentration of AI-biology venture capital.
Key Insights Summary
- AlphaFold has been used by over 3 million researchers in more than 190 countries as of November 2025, according to Google DeepMind, with the AlphaFold Protein Structure Database hosting over 200 million predicted structures.
- AlphaFold 3 achieves 50% higher accuracy than the best traditional physics-based methods on the PoseBusters protein-ligand benchmark, per the May 2024 Nature publication.
- Isomorphic Labs Drug Design Engine (IsoDDE), previewed February 2026, more than doubles AlphaFold 3 accuracy on the hardest Runs N' Poses generalization category and outperforms AlphaFold 3 by 2.3x on antibody-antigen DockQ scores above 0.8.
- EvolutionaryScale's ESM3 was trained on 2.78 billion proteins with 98 billion parameters, applying over 1x10^24 FLOPS, the largest reported training compute for a protein model per the company's June 2024 disclosure.
- The University of Missouri PSBench dataset released in February 2026 contains 1.4 million annotated protein structure models, providing the largest expert-verified benchmark for AI prediction quality assessment.
- D-I-TASSER, developed at the National University of Singapore Cancer Science Institute and announced 14 February 2026, predicts complex protein structures 13% more accurately than prior state-of-the-art methods on multi-domain proteins.
- Schrödinger reported FY2024 software revenue of USD 180.4 million, with platform adoption confirmed across all top 20 pharmaceutical companies and 73-75% software gross margin guidance for 2025.
Competitive Landscape Overview
The protein structure prediction market is moderately consolidated. Google DeepMind / Isomorphic Labs, Schrödinger, Generate Biomedicines, and EvolutionaryScale together account for an estimated 55% of commercial activity by revenue and partnership value. AlphaFold 3 holds the largest researcher reach through the free non-commercial AlphaFold Server, while Schrödinger leads in physics-based commercial licensing across the top 20 pharmaceutical companies. Generate Biomedicines combines de novo design with internal therapeutic development, having filed S-1 documents for a Nasdaq IPO under ticker GENB on 4 February 2026.
Competition in the protein structure prediction market is structured around four vectors: model accuracy on hard generalization benchmarks (Runs N' Poses, PoseBusters, CASP), training compute scale and proprietary biological data access, integration with cryo-EM and high-throughput wet-lab validation pipelines, and commercial-license clarity for pharmaceutical partners. Isomorphic Labs raised USD 600 million in April 2025 led by Thrive Capital, signaling the largest single private financing in the segment to date. Open-source foundations including the Baker Lab's RoseTTAFold and RFdiffusion, alongside Meta's discontinued ESM line now continued by EvolutionaryScale, anchor academic competition. NVIDIA's BioNeMo platform and AWS HealthOmics serve as the principal compute and distribution channels, with March 2026 NVIDIA biotech collaboration expansions reinforcing GPU-led inference economics.
Competitive Landscape Matrix
| Company | HQ | Market Position | Key Product | Geographic Strength | Recent Strategic Move (Trailing 18 Months) |
|---|---|---|---|---|---|
| Google DeepMind / Isomorphic Labs | United Kingdom | Leader | AlphaFold 3, AlphaFold Server, Isomorphic Drug Design Engine (IsoDDE) | Global; partners across Europe, US, Asia | Released IsoDDE technical preview in February 2026, more than doubling AlphaFold 3 accuracy on hardest generalization benchmarks |
| Schrödinger, Inc. | United States | Leader | Maestro suite, FEP+, BioLuminate, IFD-MD | Used by all top 20 pharmaceutical companies | Reported Q3 2025 software revenue of USD 40.9 million; entered USD 150 million upfront Novartis collaboration in January 2025 |
| Generate Biomedicines | United States | Leader | Generate Platform with diffusion and graph-based protein design models | United States, Europe | Filed S-1 for Nasdaq IPO under ticker GENB on 4 February 2026; dosed first Phase 3 patient on 26 January 2026 |
| EvolutionaryScale | United States | Leader | ESM3, ESM Cambrian protein language models | Global via AWS, NVIDIA BioNeMo | Published ESM3 in Science in January 2025; opened API for biological intelligence in public beta |
| University of Washington / Baker Lab | United States | Challenger | RoseTTAFold, RFdiffusion, ProteinMPNN | Academic and partner network | David Baker shared the 2024 Nobel Prize in Chemistry on 9 October 2024 for computational protein design |
| BIOVIA (Dassault Systèmes) | France | Challenger | Discovery Studio, Insight II | Europe, North America, Asia | Integrated AI structure prediction modules into 3DEXPERIENCE platform for pharma R&D |
| Chemical Computing Group | Canada | Niche Player | Molecular Operating Environment (MOE) | Academic and biotech labs globally | Released MOE 2024 with enhanced AlphaFold integration and PSILO database support |
| NVIDIA Corporation | United States | Challenger | BioNeMo, Parabricks Inference for AlphaFold2/ESMFold/OpenFold | Global cloud and on-premises deployments | Expanded biotech collaborations for AI-driven protein design with GPU-powered platforms in March 2026 |
| Insilico Medicine | Hong Kong / United States | Challenger | Pharma.AI integrating PandaOmics, Chemistry42, InClinico | United States, China, Europe | Advanced INS018_055 (ISM001-055) into Phase IIa trials for idiopathic pulmonary fibrosis under FDA Orphan Drug status |
| NEC Corporation | Japan | Niche Player | NEC AI Drug Discovery, NEC OncoImmunity | Japan, ASEAN | Launched AI solutions for protein analysis and design targeting pharmaceutical applications in January 2026 |
By Offering
The protein structure prediction market by offering is led by software and platform licensing, which captured approximately 68.5% of revenue in 2025, equivalent to roughly USD 0.29 Billion. Schrödinger, BIOVIA Discovery Studio, Chemical Computing Group MOE, and OpenEye Scientific anchor the licensed-software tier with multi-year enterprise contracts at all top 20 pharmaceutical companies. Cloud and API access through AlphaFold Server, EvolutionaryScale Forge, NVIDIA BioNeMo, and AWS HealthOmics represent the fastest-growing sub-segment, with usage-based pricing replacing perpetual licenses for academic and small-biotech users.
Services and integrated drug discovery collaborations accounted for the remaining 31.5% of revenue, equivalent to USD 0.13 Billion in 2025. This sub-segment is dominated by structure-prediction-enabled drug discovery deals such as the Schrödinger-Novartis collaboration (USD 150 million upfront, January 2025, up to USD 2.3 billion in milestones), the Generate Biomedicines-Novartis multi-target collaboration (USD 65 million upfront, more than USD 1 billion total), and Isomorphic Labs partnerships with Eli Lilly and Novartis worth approximately USD 3 billion across 2024-2025. The protein structure prediction market vendor procurement checklist for pharmaceutical buyers typically requires GxP audit support, validated FEP+ accuracy with mean unsigned errors of 0.8-1.2 kcal/mol, and SOC 2 Type II compliance for cloud deployments.
By Technology
Deep learning sequence-based models led the protein structure prediction market by technology with approximately 52.0% revenue share in 2025. AlphaFold 2, AlphaFold 3, ESMFold, and OpenFold represent this category, integrating evolutionary information through multiple sequence alignments (MSAs) and graph neural network architectures. AlphaFold 3 introduced diffusion-based atomic coordinate generation for protein-DNA, protein-RNA, and protein-ligand complexes per its May 2024 Nature publication. ESMFold and ESM3 from EvolutionaryScale dispense with MSAs entirely, relying on protein language model embeddings for inference speed at the cost of marginal accuracy on highly conserved targets.
Physics-based and hybrid approaches accounted for approximately 32.5% of the protein structure prediction market in 2025. Schrödinger's free energy perturbation (FEP+), molecular dynamics, and Monte Carlo sampling complement AI prediction with quantitative thermodynamic accuracy. Hybrid models including D-I-TASSER from NUS, announced 14 February 2026 with 13% accuracy gains on multi-domain proteins, combine deep learning with physics-based assembly. Diffusion generative models including RFdiffusion (Baker Lab) and Chroma (Generate Biomedicines) captured the remaining 15.5%, with disproportionate attention given the de novo protein design opportunity.
By Application
Drug discovery and lead optimization led the protein structure prediction market with 33.7% revenue share in 2025, equivalent to approximately USD 0.14 Billion. Structure-based drug design uses predicted binding pockets and protein-ligand poses to prioritize chemistry, with Isomorphic Labs IsoDDE demonstrating the ability to identify novel binding pockets from amino acid sequence alone per its February 2026 technical preview. Antibody and biologics design represents the second-largest application at 22.4%, supported by Generate Biomedicines, Absci, and EvolutionaryScale platforms; IsoDDE's CDR-H3 loop prediction unlocks de novo antibody design for the most variable antibody region.
Academic and basic research applications captured 18.6% of revenue. AlphaFold's 20,000+ scientific citations underscore depth of basic research penetration. Enzyme engineering, vaccine design, and synthetic biology applications represent the remaining 25.3% combined. Industrial enzyme engineering uses AlphaFold and ProteinMPNN to optimize thermostability and substrate specificity; vaccine programs deploy structure prediction to design epitope-displaying nanoparticles, with the Baker Lab's January 2026 publication describing de novo protein nanoparticles with integrated functional motifs. The protein structure prediction ROI calculation in pharmaceutical settings typically values one validated novel binding pocket at USD 5-15 million in saved screening cost relative to traditional fragment-based discovery.
By End-User
Pharmaceutical and biotechnology companies accounted for approximately 58.4% of protein structure prediction market revenue in 2025. Schrödinger's customer base of all top 20 pharmaceutical companies includes Pfizer, Roche, Novartis, Johnson & Johnson, AbbVie, Merck, AstraZeneca, Eli Lilly, and Novo Nordisk. Academic and government research institutions captured 27.1%, supported by NIH grants, EU Horizon Europe funding, and equivalent programs in China and Japan. Contract research organizations including WuXi AppTec, Charles River, and Catalent represent 9.3%, while industrial enzyme producers (Novozymes, BASF Enzymes) and food-tech companies cover the residual 5.2%.
Regional Analysis
North America
North America led the protein structure prediction market with 41.0% revenue share in 2025, equivalent to approximately USD 0.17 Billion. The United States accounts for over 92% of regional demand, supported by NIH research funding exceeding USD 47 billion annually, Department of Energy BOTTLE program protein engineering grants, and concentration of AI-biology venture capital. Schrödinger (Nasdaq: SDGR), Generate Biomedicines, EvolutionaryScale, and Insilico Medicine US operations anchor the regional supplier base. The FDA's acceptance of over 500 submissions with AI components between 2016 and 2023 and the Insilico Medicine INS018_055 Orphan Drug Designation in February 2023 demonstrate regulatory comfort with AI-discovered molecules.
Europe
Europe represented approximately 27.5% of the protein structure prediction market in 2025, valued at USD 0.12 Billion. The European Bioinformatics Institute (EMBL-EBI) co-hosts the AlphaFold Protein Structure Database with Google DeepMind, providing the open-access foundation for European research. Isomorphic Labs (London) and Cradle (Zurich, Amsterdam) anchor commercial activity. Horizon Europe funding directs over EUR 95 billion across 2021-2027, with structural biology programs receiving dedicated allocations. The EU AI Act, in force since 2 August 2024, applies to general-purpose AI models including protein language models exceeding the 10^25 FLOPS systemic risk threshold, although ESM3's 10^24 FLOPS training compute remains below this cutoff.
Asia Pacific
Asia Pacific accounted for approximately 22.8% of the protein structure prediction market in 2025, valued at USD 0.10 Billion, and is forecast to lead growth through 2034. China leads regional demand, supported by the Ministry of Science and Technology AI for Science programs and BGI Genomics infrastructure. Japan's NEC Corporation launched dedicated AI protein analysis solutions in January 2026 targeting domestic pharmaceutical applications. The National University of Singapore announced D-I-TASSER on 14 February 2026, advancing multi-domain protein modeling accuracy by 13% over prior methods. Insilico Medicine's Hong Kong base supports AI drug discovery operations across the region.
Latin America
Latin America held approximately 5.7% of the protein structure prediction market in 2025, equivalent to USD 0.024 Billion. Brazil leads regional adoption, supported by FAPESP (Sao Paulo Research Foundation) computational biology grants and Fiocruz vaccine R&D programs. Mexico, Argentina, and Chile have introduced national AI strategies that include life sciences applications, although industrial-scale pharmaceutical R&D investment remains limited. Regional procurement teams evaluating protein structure prediction implementation timelines should weigh cloud-based AlphaFold Server access against on-premises GPU deployment costs that remain prohibitive for most regional academic institutions.
Middle East & Africa
Middle East & Africa accounted for approximately 3.0% of the protein structure prediction market in 2025, equivalent to USD 0.013 Billion. Saudi Arabia's King Abdullah University of Science and Technology (KAUST), the United Arab Emirates' Mohamed bin Zayed University of Artificial Intelligence (MBZUAI), and the Israeli computational biology ecosystem anchor regional research activity. Saudi Arabia's Vision 2030 includes biotech industry development targets, with public investment funds backing computational biology partnerships. South Africa's National Research Foundation supports limited structural biology programs at the University of Cape Town and University of the Witwatersrand.
Country Analysis
United States
The United States protein structure prediction market reached approximately USD 0.16 Billion in 2025, with country CAGR of 28.2% projected through 2034. Federal research funding through the National Institutes of Health (USD 47.7 billion FY2024 budget), the Department of Energy BOTTLE program, and NSF AI Institutes anchors academic demand. The U.S. FDA accepted over 500 AI-related drug submissions between 2016 and 2023 and granted Insilico Medicine the first Orphan Drug Designation for an AI-discovered molecule in February 2023. Schrödinger (Nasdaq: SDGR) reported USD 180.4 million in 2024 software revenue and entered a USD 150 million Novartis collaboration in January 2025. The Defense Advanced Research Projects Agency (DARPA) AI Forward and Biological Technologies Office programs fund dual-use protein design research.
United Kingdom
The United Kingdom protein structure prediction market reached approximately USD 0.045 Billion in 2025, with country CAGR of 30.1% projected. London-based Isomorphic Labs anchored regional activity, raising USD 600 million from Thrive Capital and Alphabet in April 2025 and partnering with Novartis and Eli Lilly on agreements jointly worth nearly USD 3 billion across 2024-2025. The Wellcome Trust funds open-access protein database infrastructure, while UKRI's GBP 8 billion AI investment program includes life sciences applications. EMBL-EBI's Hinxton campus co-hosts the AlphaFold Protein Structure Database. The UK Bioscience Sector Deal directs continued public-private investment, with the AI Safety Institute coordinating model evaluation including protein design risk assessments.
China
China's protein structure prediction market reached approximately USD 0.040 Billion in 2025, with country CAGR of 32.5% projected through 2034. The Ministry of Science and Technology directed approximately USD 1.4 billion to AI for Science programs spanning 2024-2026, with structural biology and protein design among priority domains. BGI Genomics, Tencent AI Lab, and Baidu Research operate dedicated protein structure prediction teams. Insilico Medicine's Hong Kong operations support the Pharma.AI platform serving Chinese and global pharmaceutical customers. CASP16 (the 16th Critical Assessment of Protein Structure Prediction) included multiple Chinese teams in the top performers, signaling growing domestic capability.
Japan
Japan's protein structure prediction market reached approximately USD 0.030 Billion in 2025, with country CAGR of 26.8% projected. The Japan Agency for Medical Research and Development (AMED) funds structural biology and AI drug discovery programs at RIKEN, Kyoto University, and the University of Tokyo. NEC Corporation launched AI solutions for protein analysis and design in January 2026, targeting pharmaceutical applications. Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, and Astellas Pharma have integrated AlphaFold and Schrödinger workflows into discovery pipelines. The Pharmaceuticals and Medical Devices Agency (PMDA) issued draft guidance in 2024 on the use of AI-derived evidence in drug submissions, formalizing regulatory acceptance.
Protein Structure Prediction Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
28.6%
The Forecast Market
Size for 2034 in USD:
$USD 4.05 B
Get more details on this report -
Key Market Segments
By Offering
- Software and Platforms
- Databases and Knowledge Repositories
- Cloud-Based Prediction Services
- Professional and Consulting Services
- Computational Biology Services
- Bioinformatics and Data Analysis Services
- Training and Support Services
- Others
By Technology
- Artificial Intelligence (AI)-Based Prediction
- Machine Learning Algorithms
- Homology Modeling
- Ab Initio Modeling
- Threading and Fold Recognition
- Molecular Dynamics Simulation
- Hybrid Modeling Approaches
- Deep Learning-Based Prediction
- Quantum Computing-Assisted Prediction
- Others
By Application
- Drug Discovery and Development
- Protein Engineering
- Precision Medicine
- Antibody Design and Optimization
- Vaccine Development
- Biomarker Discovery
- Genomics and Proteomics Research
- Enzyme Engineering
- Cell and Gene Therapy Research
- Academic Research
- Agricultural Biotechnology
- Industrial Biotechnology
- Others
By End-User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Clinical Research Organizations
- Healthcare and Diagnostic Institutions
- Government and Public Research Agencies
- Agricultural Biotechnology Companies
- Industrial Biotechnology Companies
- Bioinformatics Service Providers
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 0.42 B |
| Forecast Revenue (2034) | USD 4.05 B |
| CAGR (2025-2034) | 28.6% |
| Historical data | |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Offering, (Software and Platforms, Databases and Knowledge Repositories, Cloud-Based Prediction Services, Professional and Consulting Services, Computational Biology Services, Bioinformatics and Data Analysis Services, Training and Support Services, Others), By Technology, (Artificial Intelligence (AI)-Based Prediction, Machine Learning Algorithms, Homology Modeling, Ab Initio Modeling, Threading and Fold Recognition, Molecular Dynamics Simulation, Hybrid Modeling Approaches, Deep Learning-Based Prediction, Quantum Computing-Assisted Prediction, Others), By Application, (Drug Discovery and Development, Protein Engineering, Precision Medicine, Antibody Design and Optimization, Vaccine Development, Biomarker Discovery, Genomics and Proteomics Research, Enzyme Engineering, Cell and Gene Therapy Research, Academic Research, Agricultural Biotechnology, Industrial Biotechnology, Others), By End-User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Clinical Research Organizations, Healthcare and Diagnostic Institutions, Government and Public Research Agencies, Agricultural Biotechnology Companies, Industrial Biotechnology Companies, Bioinformatics Service Providers, Others) |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | GOOGLE DEEPMIND / ISOMORPHIC LABS, SCHRÖDINGER, INC., GENERATE BIOMEDICINES, INC., EVOLUTIONARYSCALE, UNIVERSITY OF WASHINGTON / BAKER LAB (ROSETTAFOLD, RFDIFFUSION), BIOVIA (DASSAULT SYSTÈMES), CHEMICAL COMPUTING GROUP, OPENEYE SCIENTIFIC SOFTWARE, NVIDIA CORPORATION (BIONEMO), INSILICO MEDICINE, ABSCI CORPORATION, CRADLE BIO, PROFLUENT BIO, A-ALPHA BIO, INC., ARZEDA CORP., NEC CORPORATION, OPENPROTEIN.AI, RECURSION PHARMACEUTICALS, Others |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Protein Structure Prediction Market?
The Global Protein Structure Prediction Market was valued at USD 0.33 Billion in 2024 and USD 0.42 Billion in 2025, and is projected to reach USD 4.05 Billion by 2034, growing at a CAGR of 28.6% from 2026 to 2034. Market growth is driven by advancements in AI-powered computational biology, increasing demand for accelerated drug discovery, and expanding applications in precision medicine and biologics development.
Who are the major players in the Protein Structure Prediction Market?
GOOGLE DEEPMIND / ISOMORPHIC LABS, SCHRÖDINGER, INC., GENERATE BIOMEDICINES, INC., EVOLUTIONARYSCALE, UNIVERSITY OF WASHINGTON / BAKER LAB (ROSETTAFOLD, RFDIFFUSION), BIOVIA (DASSAULT SYSTÈMES), CHEMICAL COMPUTING GROUP, OPENEYE SCIENTIFIC SOFTWARE, NVIDIA CORPORATION (BIONEMO), INSILICO MEDICINE, ABSCI CORPORATION, CRADLE BIO, PROFLUENT BIO, A-ALPHA BIO, INC., ARZEDA CORP., NEC CORPORATION, OPENPROTEIN.AI, RECURSION PHARMACEUTICALS, Others
Which segments covered the Protein Structure Prediction Market?
By Offering, (Software and Platforms, Databases and Knowledge Repositories, Cloud-Based Prediction Services, Professional and Consulting Services, Computational Biology Services, Bioinformatics and Data Analysis Services, Training and Support Services, Others), By Technology, (Artificial Intelligence (AI)-Based Prediction, Machine Learning Algorithms, Homology Modeling, Ab Initio Modeling, Threading and Fold Recognition, Molecular Dynamics Simulation, Hybrid Modeling Approaches, Deep Learning-Based Prediction, Quantum Computing-Assisted Prediction, Others), By Application, (Drug Discovery and Development, Protein Engineering, Precision Medicine, Antibody Design and Optimization, Vaccine Development, Biomarker Discovery, Genomics and Proteomics Research, Enzyme Engineering, Cell and Gene Therapy Research, Academic Research, Agricultural Biotechnology, Industrial Biotechnology, Others), By End-User, (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Clinical Research Organizations, Healthcare and Diagnostic Institutions, Government and Public Research Agencies, Agricultural Biotechnology Companies, Industrial Biotechnology Companies, Bioinformatics Service Providers, Others)
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Protein Structure Prediction Market
Published Date : 15 Jun 2026 | Formats :Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date